23 May 2013
Keywords: ma, gtc, bio, atryn, goes, leo, firm
Article | 08 January 2007
US firm GTC Biotherapeutics says that the market authorization of ATryn for the prophylaxis of venous thromboembolism in surgery of ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
15 January 2007
22 January 2007
© 2013 thepharmaletter.com